Published in Bone Marrow Transplant on June 01, 1995
ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center (ATG/PTCy) | NCT03608059
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med (2016) 2.76
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant (2007) 2.60
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 2.49
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol (2010) 2.31
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood (2009) 2.12
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 2.10
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood (2011) 2.03
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant (2011) 2.02
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood (2015) 2.00
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol (2014) 1.97
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood (2006) 1.95
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med (2016) 1.88
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood (2009) 1.86
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood (2013) 1.84
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant (2009) 1.84
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood (2013) 1.82
Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood (2006) 1.82
Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. Cell Stem Cell (2015) 1.82
Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood (2012) 1.81
Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol (2000) 1.80
Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res (2011) 1.78
Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood (2011) 1.76
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 1.74
Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood (2013) 1.72
Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant (2012) 1.72
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood (2014) 1.71
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol (2015) 1.70
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood (2009) 1.70
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol (2012) 1.68
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood (2015) 1.66
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 1.65
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol (2009) 1.65
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol (2013) 1.64
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood (2014) 1.64
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol (2008) 1.63
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood (2009) 1.62
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant (2013) 1.62
Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood (2014) 1.60
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood (2008) 1.59
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.58
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant (2011) 1.57
The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2009) 1.56
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood (2012) 1.55
Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2012) 1.55
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 1.55
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood (2013) 1.54
Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood (2005) 1.54
Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2010) 1.53
How I assess comorbidities before hematopoietic cell transplantation. Blood (2013) 1.52
Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.52
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood (2015) 1.52
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
The repair of double-strand breaks in the nuclear DNA of Saccharomyces cerevisiae and its genetic control. Mol Gen Genet (1976) 6.89
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Alternative definitions of disability: relationship to health-care expenditures. Disabil Rehabil (1997) 5.50
Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545. Nucleic Acids Res (1986) 4.47
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science (1982) 4.07
A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet (1979) 4.01
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis (1986) 3.31
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia. Infect Immun (1982) 3.22
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Iron Metabolism. Heme Synthesis in Vitro by Immature Erythrocytes. Science (1949) 3.14
Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 3.05
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol (2000) 2.78
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (1994) 2.65
Mechanisms of epithelial fusion and repair. Nat Cell Biol (2001) 2.63
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Failure of silicone gel breast implants: analysis of literature data for 1652 explanted prostheses. Plast Reconstr Surg (1997) 2.56
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J (1984) 2.55
Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med (1993) 2.52
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis (1983) 2.39
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther (2013) 2.38
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (1995) 2.33
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
T lymphocyte adhesion to endothelial cells: mechanisms demonstrated by anti-LFA-1 monoclonal antibodies. J Immunol (1986) 2.28
Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24
Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science (1976) 2.23
Safeguards for research using large scale DNA collections. BMJ (2000) 2.22
Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology (1984) 2.19
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat (2013) 2.15
Putting ion channels to work: mechanoelectrical transduction, adaptation, and amplification by hair cells. Proc Natl Acad Sci U S A (2000) 2.15
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet (1972) 2.13
Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene. Science (1984) 2.12
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. J Cell Biol (1996) 2.12
A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis (1977) 2.10
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature (1987) 2.04
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03
Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med (1983) 2.03
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med (1986) 1.99
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood (1994) 1.98
[Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants]. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
Infection due to Corynebacterium species in marrow transplant patients. Ann Intern Med (1979) 1.94
Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci (2000) 1.92
Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91
Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol (1997) 1.91
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology (1980) 1.88
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Technique for human marrow grafting. Blood (1970) 1.83
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther (2003) 1.82
Identification of grandchildless loci whose products are required for normal germ-line development in the nematode Caenorhabditis elegans. Genetics (1991) 1.81
Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med (1975) 1.80
Transforming viruses directly reduce the cellular growth requirement for a platelet derived growth factor. J Cell Physiol (1978) 1.79
Leukaemic transformation of engrafted human marrow cells in vivo. Lancet (1971) 1.79
Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.77
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Validation of a model of colon cancer progression. J Pathol (2000) 1.76
Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse. J Cell Sci (1994) 1.74
99mTc-tagged chicken liver as a marker of solid food in the human stomach. Am J Dig Dis (1976) 1.74
Bone marrow grafts and tolerance. Nature (1986) 1.74
Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens (1996) 1.73
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
Role of sympathectomy for hyperhidrosis. Br Med J (1971) 1.68
Localized two-dimensional shift correlated MR spectroscopy of human brain. Magn Reson Med (2001) 1.67
Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol (1988) 1.66
Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65
Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard genotyping methodologies. J Clin Microbiol (1995) 1.65
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients. Br J Haematol (1980) 1.63